Proteine Resources launches VELI wet pet food line at Interzoo

Proteine Resources has used Interzoo 2026 to debut VELI, a functional wet pet food line centered on EntoPro, its proprietary alternative protein ingredient made from insect protein and mushroom cultivation byproducts. The launch positions the company in a crowded alternative-protein field, but with a more specific pitch: not just sustainability or novelty, but GI and skin support in a wet format for dogs and cats. Interzoo ran May 12-15, 2026, in Nuremberg and featured heavy interest in ingredient innovation, including insect-based offerings. (interzoo.com)

The launch has been several years in the making. Proteine Resources previously said it had patented the EntoPro production process and was preparing ready-to-market formulations under a private-label model after securing investment for an alternative protein facility. The company now says the broader platform reflects about eight years of cumulative R&D, including work on the core protein system and later formulation development for VELI itself. (petfoodmedia.com)

At the ingredient level, EntoPro is being presented as more than an insect meal. Company materials describe it as a hybrid matrix combining insect-derived protein with mushroom-sourced bioactive compounds, with prebiotic chitin and postbiotics intended to support the gut-immune axis. Proteine Resources says the postbiotics were selected in part because they remain stable during wet food sterilization, a practical formulation point for canned or pouch products where live probiotics may be harder to preserve. The company also claims digestibility above 85% and says the amino acid profile matches beef on a 1:1 basis, though those claims come from company materials rather than an independently published paper. (petfoodmedia.com)

The evidence base, at least publicly, is still emerging. Proteine Resources says large-scale in vitro studies were conducted with the University of Agriculture in Krakow and that formal in vivo holistic testing is now launching. That distinction matters. In vitro findings can help support mechanism and formulation rationale, but they don’t substitute for controlled feeding studies showing clinical benefit in companion animals. For veterinary teams evaluating these products, the difference between “functional” and “clinically proven” remains important, especially when products are marketed around common complaints like vomiting, diarrhea, pruritus, or skin barrier support. (petfoodmedia.com)

The broader market context helps explain the timing. Insect protein has gained traction in European pet food as manufacturers look for novel proteins with sustainability appeal and lower reliance on conventional livestock inputs. FEDIAF notes that insect-based ingredients are increasingly accepted in pet food, while also acknowledging that more long-term research is needed to substantiate some health and sustainability claims. Interzoo 2026 itself highlighted sustainable protein as a major theme, suggesting that VELI is arriving into a receptive B2B environment rather than trying to create a category from scratch. (europeanpetfood.org)

For veterinary professionals, the most relevant question is whether products like VELI can become credible tools for nutrition-led management of GI sensitivity and dermatologic issues, or whether they’ll remain mostly a premium positioning story. There is a plausible clinical rationale here: novel proteins can be useful in some diet trials, fiber fractions may influence the microbiome, and postbiotics are attracting interest because they may be more formulation-stable than live microbes. Still, veterinary confidence will likely depend on published feeding data, clearer nutrient adequacy information, and transparent claim boundaries. FDA states that pet food in the U.S. must be safe, truthfully labeled, and use ingredients with an appropriate function, and it draws a line when labeling suggests diagnosis, cure, mitigation, treatment, or prevention of disease. FDA also notes that it does not pre-approve final packaged pet food formulations before marketing. (fda.gov)

Regulatory geography is another issue to watch. In Europe, insect-derived materials already have an established pathway into feed and pet food markets, and industry groups describe insect ingredients as a growing part of the companion animal nutrition toolkit. In the U.S. and Canada, Proteine Resources says certification is still planned, which suggests commercialization there may depend as much on ingredient clearance and labeling strategy as on demand. That matters for clinics, because products positioned as “functional” can reach pet parents quickly online or through specialty retail, sometimes before veterinarians have much published evidence to work with. (petfoodmedia.com)

Why it matters: VELI reflects a broader shift in pet nutrition toward products that borrow the language of microbiome science, functional ingredients, and condition-specific support. For veterinarians, that creates both opportunity and friction. These diets may eventually expand options for pets with food sensitivities or chronic GI issues, but the clinical bar remains higher than a trade-show debut or company-run palatability testing. The practical task for veterinary teams will be separating ingredient promise from demonstrated patient benefit, while helping pet parents understand what is, and isn’t, proven yet. (petfoodmedia.com)

What to watch: The next milestones are publication of in vivo data, any third-party or peer-reviewed validation of EntoPro’s functional claims, and progress on North American regulatory acceptance and commercial rollout. (petfoodmedia.com)